DK1210430T3 - MUC-1-afledte peptider - Google Patents

MUC-1-afledte peptider

Info

Publication number
DK1210430T3
DK1210430T3 DK00965943T DK00965943T DK1210430T3 DK 1210430 T3 DK1210430 T3 DK 1210430T3 DK 00965943 T DK00965943 T DK 00965943T DK 00965943 T DK00965943 T DK 00965943T DK 1210430 T3 DK1210430 T3 DK 1210430T3
Authority
DK
Denmark
Prior art keywords
muc
polypeptides
peptides
derived peptides
derived
Prior art date
Application number
DK00965943T
Other languages
English (en)
Inventor
Rienk Offringa
Bruce Acres
Lukas Carl Heukamp
Cornelis Johanna Maria Melief
Joyce Taylor-Papadimitriou
Mireille Thomas
Original Assignee
Transgene Sa
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921242.5A external-priority patent/GB9921242D0/en
Application filed by Transgene Sa, Imp Cancer Res Tech filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1210430T3 publication Critical patent/DK1210430T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00965943T 1999-09-08 2000-09-07 MUC-1-afledte peptider DK1210430T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9921242.5A GB9921242D0 (en) 1999-09-08 1999-09-08 Cancer vaccine and diagnosis
EP99402237 1999-09-10
US18721500P 2000-03-03 2000-03-03

Publications (1)

Publication Number Publication Date
DK1210430T3 true DK1210430T3 (da) 2006-11-20

Family

ID=27240232

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00965943T DK1210430T3 (da) 1999-09-08 2000-09-07 MUC-1-afledte peptider

Country Status (11)

Country Link
US (3) US20050142640A1 (da)
EP (1) EP1210430B1 (da)
JP (1) JP2003510094A (da)
AT (1) ATE338121T1 (da)
AU (1) AU778701B2 (da)
CA (1) CA2383737C (da)
DE (1) DE60030450T2 (da)
DK (1) DK1210430T3 (da)
ES (1) ES2270870T3 (da)
PT (1) PT1210430E (da)
WO (1) WO2001018035A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004212A1 (en) * 1997-12-30 2009-01-01 Franz-Georg Hanisch Tumour vaccines for MUC1-positive carcinomas
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
AU2002246791C1 (en) 2000-12-22 2008-04-03 Dana-Farber Cancer Institute, Inc. Regulation of cell growth by MUC1
WO2002076485A2 (en) 2001-03-27 2002-10-03 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
ATE494387T1 (de) 2001-11-07 2011-01-15 Mannkind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US20030235868A1 (en) * 2002-04-22 2003-12-25 Dyax Corporation Antibodies specific for mucin polypeptide
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
TWI395591B (zh) 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
PT1896051E (pt) * 2005-06-28 2015-01-13 Oncothyreon Inc Método de tratamento de pacientes com uma vacina de glicoproteína mucinosa (muc-1)
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
CA2665816C (en) 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
EP2250189A4 (en) * 2008-02-26 2012-07-04 Univ California GYLCOPEPTIDES AND METHOD FOR THEIR PREPARATION AND USE
AU2009305550B2 (en) 2008-10-17 2014-06-12 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
CN102665748A (zh) 2009-05-27 2012-09-12 达娜-法勃肿瘤研究所公司 使用muc1拮抗剂抑制炎症
US8685928B2 (en) 2010-02-12 2014-04-01 Dana-Farber Cancer Institute, Inc. Antagonists of MUC1
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
JP6096111B2 (ja) 2010-05-10 2017-03-15 アセンド・バイオファーマシューティカルズ・リミテッド 免疫刺激組成物及びワクチン組成物
CN105193724A (zh) 2011-02-24 2015-12-30 肿瘤防护公司 含有佐剂的以muc1 为基础的糖脂肽疫苗
CN114617958A (zh) 2011-08-17 2022-06-14 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
DK2800762T3 (da) * 2012-01-03 2018-04-16 Us Health Native og agonistiske ctl-epitoper af muc1-tumor-antigenet
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
EP3269726A4 (en) * 2015-03-09 2018-12-05 Nec Corporation Peptide derived from muc1, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cells
EP3903811A1 (en) * 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmaceutical composition and method for inducing an immune response

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
JPH02273195A (ja) * 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
JPH08501280A (ja) * 1992-05-26 1996-02-13 リュクスウニヴェルシテート レイデン ヒトＴ細胞応答誘発組成物に用いるためのヒトｐ５３タンパク質のペプチドおよびヒトｐ５３タンパク質特異的細胞毒性Ｔリンパ球
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
EP0986636B1 (en) * 1997-05-08 2008-05-07 Biomira, Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
CA2322444A1 (en) * 1998-03-05 1999-09-10 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies

Also Published As

Publication number Publication date
ES2270870T3 (es) 2007-04-16
CA2383737A1 (en) 2001-03-15
US20100255501A1 (en) 2010-10-07
WO2001018035A3 (en) 2001-11-08
US20050142640A1 (en) 2005-06-30
PT1210430E (pt) 2006-12-29
WO2001018035A2 (en) 2001-03-15
ATE338121T1 (de) 2006-09-15
AU778701B2 (en) 2004-12-16
CA2383737C (en) 2011-01-18
WO2001018035A9 (en) 2002-09-06
AU7651500A (en) 2001-04-10
EP1210430B1 (en) 2006-08-30
US7892828B2 (en) 2011-02-22
DE60030450T2 (de) 2007-08-30
EP1210430A2 (en) 2002-06-05
US20080227082A1 (en) 2008-09-18
JP2003510094A (ja) 2003-03-18
DE60030450D1 (de) 2006-10-12

Similar Documents

Publication Publication Date Title
DK1210430T3 (da) MUC-1-afledte peptider
NZ511454A (en) Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
PT920510E (pt) Quimeras de gnrh-leucotoxina
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
NO20050066L (no) Pegylert T20 polypeptid
DE69320967D1 (de) Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
GB9219936D0 (en) Vaccines
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DK0996726T3 (da) T-celle-membranprotein (TIRC7), peptider og antistoffer afledt deraf og anvendelse deraf
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE
FI953093A (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
DE60118359D1 (de) Humanische pellino-polypeptide
ES2152313T3 (es) Gen grb-3-3, sus variantes y sus utilizaciones.
ATE362939T1 (de) Dimere von thrombinpeptidderivaten
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
BR0114977A (pt) segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
WO2001011937A3 (en) Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
ATE281524T1 (de) Moraxella catarrhalis pilq proteine
DK0646016T3 (da) Syntetiske peptider til behandlling af myasthenia gravis